Table 2.

Donor specific antibodies: characteristics, kinetics and management.

	Patients (n=69)
Baseline DSA characteristics (n, %)  • DSA anti-MHC class I only  • Intensity >5,000 MFI  • DSA anti-MHC class II only  • Intensity >5,000 MFI  • DSA anti-MHC class I and II  • Intensity >5,000 MFI	33 (48) 24 19 (27) 7 17 (25) 15
Baseline DSA intensity (n, %)  • >5,000 MFI  • >10,000 MFI  • >20,000 MFI	46 (67) 21 (30) 3 (4)
Complement fixation techniques available (n, %)  • Positive C1q/C3d fixation	20 (29) 14
Patients receiving desensitization (n, %)  • Rituximab  • IVIG  • TPE  • Incompatible platelet transfusion  • MMF  • Tacrolimus  • Buffy coat  • Bortezomib  • Steroids	63 (91) 53 (84) 42 (67) 33 (52) 26 (41) 26 (41) 13 (21) 12 (19) 2 (3) 1 (2)
Monitoring performed after desensitization (n, %)  • Patients tested after desensitization  • Patients with reduction in intensity   • Median reduction in intensity (median %, range)*  • Persistent DSA >5,000 MFI at infusion  • Persistent DSA >10,000 MFI at infusion  • Increase after infusion	(% of 63 desensitized patients) 48 (76) 45 (71) 100 (12─100) 11 (17) 3 (5) 3 (5)

DSA, donor-specific antibodies; IVIG, intravenous immunoglobulin; MFI, mean fluorescence intensity; MHC, major histocompatibility complex; MMF, mycophenolate mofetil; TPE, therapeutic plasma exchange.